Denials, Delays and Deep Discounts in Pharmaceutical Launch

The Syneos Health Podcast

FDA approval is no longer the finish line in the race to product launch success. Access and adoption have risen to the forefront as a major post-approval hurdle: recent research from Syneos Health Consulting’s Value and Access team shows that less than half of newly approved drugs appeared on formulary in their launch year. So what’s a drug developer to do?

Co-authors of the report on insurance coverage of new drugs at launch Jeff Stewart, Brian Cotten and Heather Martin discuss the results of their analysis, what developers can expect from payers in launch year, and how they can prepare the best possible access outcome for their new drug.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [e-mail].

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [e-mail].